Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,035 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Soft Tissue Tumor Clear all
Recruiting Phase 1 Interventional

IDOV-Immune for Advanced Solid Tumors

NCT06910657
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01666444
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
136
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting No phase listed Observational

Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?

NCT03261544
View directory record Official record
Conditions
Sarcoma, Bone Metastases, Proximal Femur Replacement
Interventions
Proximal Femur Replacement
Procedure
Lead sponsor
Duke University
Other
Eligibility
16 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

NCT03641287
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Transitional Cell Carcinoma
Interventions
Exercise Counseling, Aerobic Exercise, Physiological Support, Quality-of-Life Assessment, Questionnaire Administration, Best Practice
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 20, 2026, 4:03 AM EDT
Active, not recruiting Phase 2 Interventional

MR-HIFU Treatment of Painful Osteoid Osteoma

NCT04658771
View directory record Official record
Conditions
Osteoid Osteoma
Interventions
MR-HIFU treatment
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
0 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting No phase listed Observational

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

NCT03141021
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2053
U.S. locations
9
States / cities
Tampa, Florida • Baltimore, Maryland • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

NCT02229981
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
Interventions
ABC294640
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional Results available

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

NCT00372567
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
sunitinib malate, imatinib mesylate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Detroit, Michigan • Farmington Hills, Michigan • City of Saint Peters, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Not applicable Interventional Results available

Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds

NCT02638298
View directory record Official record
Conditions
Sarcoma, Cancer, Infectious Disease
Interventions
Prevana Dressing, Standard Dry Gauze Dressing
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

NCT01391611
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
Pazopanib
Drug
Lead sponsor
Kristen Ganjoo
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

NCT00390234
View directory record Official record
Conditions
Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
Interventions
ziv-aflibercept
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

NCT01016730
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
Interventions
Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 20, 2026, 4:03 AM EDT
Completed No phase listed Observational

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

NCT00026728
View directory record Official record
Conditions
Kaposi's Sarcoma, Herpesviridae Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

NCT00958334
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex®
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated No phase listed Observational

Permission to Collect Blood Over Time for Research

NCT00767234
View directory record Official record
Conditions
Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatobiliary Neoplasm, Liver Carcinoma, Gallbladder Carcinoma, Bile Duct Carcinoma, Carcinoma of the Large Intestine, Anal Cancer
Interventions
Observation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 20, 2026, 4:03 AM EDT
Not listed Phase 2 Interventional

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

NCT03420014
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Doxorubicin, L19TNF plus doxorubicin
Drug · Combination Product
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
16 Years to 100 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Implementation of Uterine Fibroid Option Grid Patient Decision Aids Across Five Organizational Settings

NCT03985449
View directory record Official record
Conditions
Uterine Fibroid
Interventions
Uterine Fibroid Option Grid encounter patient decision aid (text only), Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures), Uterine Fibroid Option Grid encounter patient decision aid (online)
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting Phase 2 Interventional

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

NCT06176989
View directory record Official record
Conditions
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma, Metastatic Large-cell Neuroendocrine Carcinoma, Locally Advanced Large-cell Neuroendocrine Carcinoma, Metastatic Olfactory Neuroblastoma, Locally Advanced Olfactory Neuroblastoma, Metastatic Sinonasal Undifferentiated Carcinoma, Locally Advanced Sinonasal Undifferentiated Carcinoma
Interventions
Enasidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Active, not recruiting Early Phase 1 Interventional

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

NCT04457258
View directory record Official record
Conditions
Metastatic Sarcoma, Recurrent Sarcoma, Sarcoma
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting Phase 1 Interventional

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

NCT04902443
View directory record Official record
Conditions
Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
Interventions
Pomalidomide, Nivolumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma

NCT00005625
View directory record Official record
Conditions
Sarcoma
Interventions
trabectedin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147158
View directory record Official record
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
61
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

NCT01593748
View directory record Official record
Conditions
Sarcoma
Interventions
Gemcitabine and Pazopanib, Gemcitabine and Docetaxel
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Phase 1 Interventional

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00427414
View directory record Official record
Conditions
Sarcoma
Interventions
liposomal daunorubicin citrate
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 20, 2026, 4:03 AM EDT